Delhi faces shortage of antiviral drug Remdesivir amid COVID-19 spike

30

New Delhi: Delhi is currently facing shortage of experimental antiviral drug Remdesivir which is being used for treating symptoms of coronavirus infection.

An increase in COVID-19 cases around the country has seen more doctors prescribing the drug, but supply hasn’t increased proportionately.

Patients are given six doses to be taken as injections. The Drug Controller General of India had on June 1 allowed Gilead Sciences, which holds the patent for Remdesivir, to start importing the medicine.

Three Indian manufacturers – Hetero, Cipla, and Mylan– have since been allowed to manufacture the drug in India.

One vial of Remdesevir by Hetero costs Rs 5,400, Cipla is yet come out with the generic version of the drug. Mumbai and Bengaluru were among the cities where several medical shops were out of stock, including the distributors.

Pharma major Cipla yesterday launched its generic version of the antiviral drug at Rs 4,000 per vial.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.